Drug intelligence / Profile preview

UGX01

Development stage: Preclinical
Lead developer: Suzhou Xingming Youjian Biotechnology
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Ophthalmic

Overview

UGX01 is an investigational adeno-associated virus (AAV) vector-based gene therapy being developed by Suzhou Xingming Youjian Biotechnology (also known as U-Genex) for the treatment of ophthalmic and retinal degenerative diseases. Positioned as a potential best-in-class (BIC) candidate, the therapy utilizes an AAV vector to deliver therapeutic genetic material directly to retinal cells to address unmet clinical needs in vision loss. It is currently in the preclinical research stage, part of a pipeline focused on conditions such as retinitis pigmentosa, age-related macular degeneration, and glaucoma.

Beyond the preview

Go deeper on UGX01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UGX01.

Explore the full profile